Clinical Trials
2 trialsNCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04197219 2020-11-05
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn